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ABSTRACT: A stereocontrolled general methodology to access all natural 
tetraponerines from (+)−T1 to (+)−T8 is detailed. Two consecutive indium-mediated 
aminoallylations with the appropriate enantiomer of chiral N-tert-butylsulfinamide and 
a thermodynamic control at the aminal stereocenter, allow the formation of each natural 
tetraponerine with excellent stereoselectivity. The use of 4-bromobutanal in the first 
aminoallylation leads to the formation of 5-6-5 tetraponerines whilst 5-bromopentanal is 
required to build the scaffold of 6-6-5 tetraponerines. A cross-metathesis reaction of the 
second aminoallylation product with cis-3-hexene is used to elongate the side chain up 
to 5 carbons so as to prepare the tetraponerines T5 to T8. The anticancer activity of 
these heavier tetraponerines against four different carcinoma human cell lines is 
examined, observing a promising cytotoxic activity of (+)−T7 against breast carcinoma 
cell line MCF-7. 
 INTRODUCTION 
Azaheterocycles with nitrogen atoms at the junction of two rings constitute a large 
group of natural alkaloids that commonly exhibit a quinolizidine or an indolizidine 
framework and display a wide range of biological activities.1 The complexity of these 
compounds is further increased by the stereochemistry of the pyramidal nitrogen at the 
ring junction, with important consequences in their bioactivities. 2  Tetraponerine 
alkaloids form a unique family of such compounds which share a quinolizidine or an 
indolizidine fragment with another indolizidine framework. These tricyclic alkaloids, 
named tetraponerines T1 to T8, possess a very uncommon aminal structure in alkaloids3 
and can be divided in two groups depending on the size of the rings: 5-6-5 or 6-6-5. In 
each group, the tetraponerines differ in the length of the alkyl chain located in C5 
(propyl or pentyl) and in the configuration of this stereocenter (Figure 1). 
 
Figure 1. Structures of natural tetraponerines. 
Tetraponerines are secreted by Pseudomyrmecine ants of the genus Tetraponera, for 
which more than 80 species can be found in Asia, Africa or Australia; being T8 the 
major tetraponerine isolated from the New Guinean ant Tetraponera, whilst T1 and T2 
are very minor naturally occurring products. It was early recognized that tetraponerines 
are paralyzing venoms segregated by the host ants against their enemies. Not 
surprisingly, it was found that they exhibit important insecticidal and neurotoxic 
biological activities.4 Recent studies categorize them as efficient inhibitors of a range of 
nAChRs (nicotinic acetylcholine receptors). 5  However, despite their interesting 
biological profile, the actual mechanisms of interaction with their corresponding 
receptors are still unknown. More recently, cytotoxic activities have also been described 
for these natural products as well as for some synthetic analogs containing long 
hydrocarbon chains at C5 position. 6  
In 1987 Braekman and co-workers reported the first isolation and structural elucidation 
of these natural products.4 The structure of T8 was unequivocally assigned by X-ray 
diffraction analysis,4 whilst the structures of the other natural tetraponerines were 
proposed by comparison of their spectroscopical data, in particular one-dimensional 1H- 
and 13C-NMR spectra, with those of T8.7 However, structures of T3, T5, T6 and T7 
were mistakenly described at first and corrected then by further studies involving 
nuclear magnetic resonance and circular dicroism.8 More recently, the combined use of 
infrared spectroscopy (IR) and mass spectrometry (MS) have also been described to 
easily identify each tetraponerine from its natural source.9 In this study it was observed 
that tetraponerines with 5-(S) configuration show more intense Bohlmann bands in the 
infrared spectra at lower vibrational frequencies than the 5-(R) isomers. 
The origin of natural tetraponerines has been studied by the Braekman's group with T610 
and T811 and different biosynthetic routes were proposed depending on the A ring size. 
Importantly, upon studies of its biochemical pathway, T8 was submitted to catalytic 
hydrogenation under acidic conditions and the N11-C11a bond was selectively cleaved, 
suggesting that the aminal core is in equilibrium with the corresponding iminium ion. 
The first enantioselective synthesis of (+)-T8 was achieved in 1990, providing a firm 
evidence of the absolute configuration of this natural alkaloid.12 The singular tricyclic 
skeleton of these alkaloids which holds an aminal moiety along with their interesting 
biological activities have made the tetraponerines very attractive targets for total 
synthesis.13 The group of Royer applied its CN (R,S) strategy14 to the synthesis of all 
natural tetraponerines known, being the only general method reported to prepare this 
entire family of alkaloids up to date.15  
Aware of the lack of detailed structural information of tetraponerines we have recently 
examined the conformational and configurational space of T3 and T4. 16 For this study 
we fixed the known configurations at C6a (R) and at C5 [(R)-for T3 and (S)- for T4] and 
considered all possible configurations at nitrogen atoms (N4 and N11) as well as at the 
aminal carbon center (C11a). The geometry of the resulting twelve configurational 
isomers (for each tetraponerine) was optimized by DFT calculations and their 
populations were estimated from the calculated energies. The first conclusion from 
these calculations is that for both T3 and T4, at least 99% of the population is 
represented by either its ttc- or ttt- isomer (Figure 2).17 A closer examination of these 
two configurational isomers shows that, despite the different fusions at the indolizidine 
frameworks, the same (S)-configuration at the aminal carbon center is observed. 
Remarkably, this configuration at C11a is observed not only for natural T3 and T4, but 
also for all the other natural tetraponerines. On the other hand, tetraponerine T3 slightly 
prefers a cis-configuration at ring C (65% of ttc-T3) while T4 is clearly dominated by a 
trans-configuration at the indolizidine framework (95% of ttt-T4). Importantly, low 
activation barriers were found for inversion of T3 and T4 at N4, which allows a fast 
equilibration between the two most populated isomers (ttc and ttt). Interestingly, 
tetraponerine analogues with a 5-5-6 tricyclic skeleton have recently been prepared in 
racemic form.18 The relative stereochemistry of these latter analogues was assigned as 
cis (fusion A/B)-transoid-trans (fusion B/C), according to NOE correlations. 
 Figure 2. Main configurational isomers previously found by DFT calculations of T3 
and T4.16 
In the present work we describe a detailed account of our stereoselective total synthesis 
of all known tetraponerines, from (+)-T1 to (+)-T8. We also provide the anticancer 
activity of C5-pentyl tetraponerines (T5 to T8) against four human cell lines. 
 
RESULTS AND DISCUSSION 
In a previous work,16 we described the total synthesis of natural tetraponerines T3 and 
T4 using a divergent approach from simple starting materials: 4-bromobutanal, 5-
bromopentanal, allylbromide and both enantiomeric forms of N-tert-butylsulfinamide.19 
As depicted in Scheme 1, the synthesis started with a 2-allylpiperidine derivative, which 
was prepared by aminoallylation of 5-bromopentanal with (R)-tert-butylsulfinamide and 
in situ generated allylindium reagent, followed by intramolecular N-alkylation. 20 
Oxidative cleavage of the double bond gave rise to the corresponding aldehyde 2, which 
was submitted to a second aminoallylation where the configuration at the new 
stereogenic center in products 3 and 4 was mainly controlled by the chiral sulfinyl 
group regardless the chirality of the aldehyde.21 This issue was crucial to prepare the 
required diamines from the same chiral aldehyde, using the appropriate enantiomer of 
chiral tert-butylsulfinamide. Acidic deprotection of the homoallylic diamines, followed 
by hydrogenation of the allyl moiety with concomitant hydrogenolysis of the carbamate 
afforded the corresponding free diamines. Without purification, these intermediates 
were put into react with 4-bromobutanal to initiate a cascade of reactions where the 
aminal formation is presumably followed by intramolecular alkylation of N4.22 This 
route allowed the preparation in good overall yields of enantiomerically pure 
tetraponerines (+)−T3 and (+)−T4 with identical spectral and physical data to the one 
reported in the literature for the natural compounds.8 Importantly, the aminal formation 
with the right stereochemistry at C11a for both compounds clearly supports the 
hypothesis of a thermodynamic control to afford the most stable aminal possible 
through equilibration with an iminium form. This idea was essential in our synthetic 
plan and comes from the following observations: a) all natural tetraponerines are 
proposed to exhibit the same configuration at the aminal carbon center, regardless the 
configuration at C5; b) during the biosynthetic studies of T8, the C11a-N11 bond was 
selectively cleaved under hydrogenation conditions.11 Moreover, our stereochemical 
analysis of tetraponerines T3 and T4 by DFT calculations indicated that both 
tetraponerines are mainly populated (> 99%) by configurational isomers (ttt and ttc) 
with (S)- configuration at C11a.  
Scheme 1. Synthesis of Tetraponerines (+)−T3 and (+)−T4 
 Prompted by these results we decided to implement the appropriate modifications to use 
the same general strategy in the synthesis of all known natural tetraponerines. As 
depicted in Scheme 2a, we recognized that the allyl group in the intermediates 3 and 4 
provides a handle to enlarge the hydrocarbonated side-chain up to 5 carbon atoms by 
cross-metathesis with an appropriate partner. Therefore, tetraponerine T7 could be 
obtained from intermediate 3 and following the same route, compound 4 could be 
carried forward to the synthesis of T8. The rest of natural tetraponerines (T1, T2, T5 
and T6) have a 5-membered ring A. Accordingly, we decided to use 4-bromobutanal in 
our aminoallylation-cyclization sequence to prepare the key 2-allylpyrrolidine 
intermediate that could be submitted to the same reaction sequence followed for the 
synthesis of 6-6-5 tetraponerines (Scheme 2b).  
Scheme 2. Modifications for the Synthesis of the other Tetraponerines 
 Synthesis of tetraponerines (+)−T7 and (+)−T8.  
Cross-metathesis is a very useful synthetic tool in the preparation of bioactive 
compounds from alkene intermediates. In this context, we 23  and others 24 have 
demonstrated that sulfinamines are tolerated by Grubbs 2nd generation catalyst 
particularly when Ti(Oi-Pr)4 is used as additive to accelerate the reaction. With these 
precedents we decided to use cis-3-hexene as cross metathesis partner25 to elongate the 
side-chain up to 5 carbons of intermediates 3 and 4, in route to the preparation of T7 
and T8, respectively. We were pleased to observe that the reaction took place smoothly 
in CH2Cl2 at 40 ºC with both protected diamines, obtaining the expected compounds in 
good yields (Scheme 3).26 After this single modification, the reaction sequence proceed 
as for compounds T3 and T4, obtaining good overall yields and excellent 
diasteroselectivities (>99:1 dr by GC) for both tetraponerines T7 and T8. NMR spectra 
were compared with the data of T3 and T4, finding the same signal pattern distinctive 
of these 6-6-5 skeletons. More importantly, the physical and spectral data of the 
synthesized (+)−T7 and (+)−T8 were in full agreement with reported values for these 
naturally occurring compounds.13b and 13c  
Scheme 3. Synthesis of (+)−T7 and (+)−T8 
  
Synthesis of tetraponerines (+)−T1, (+)−T2, (+)−T5 and (+)−T6. 
Our next goal was to extend this methodology to the synthesis of the remaining natural 
5-6-5-tetraponerines (T1, T2, T5 and T6) which differ from the others in the size of 
ring A. It is worth saying that this extension is not straightforward and our DFT 
configurational analysis was only performed for tetraponerines T3 and T4, with a 6-6-5 
pattern. The subgroup of tetraponerines with two indolizidine moieties fused in the core 
has a more flexible scaffold and the contribution of several configurational isomers 
could complicate the stereochemical landscape of these compounds. This issue has been 
so far overlooked in the literature.  
Our synthesis began with the indium-mediated aminoallylation of 4-bromobutanal with 
(RS)-tert-butylsulfinamide, followed by cyclization with KHMDS at 0 ºC. The 
corresponding 2-allylpyrrolidine 8 was obtained in good diastereoselectivity and good 
overall yield after only one purification step (Scheme 4).  
Scheme 4. Synthesis of 2-Allylpyrrolidine Intermediate 8 
 Compound 8 was a common intermediate in the synthesis of all 5-6-5 tetraponerines. 
Eventually, the nitrogen protecting group was exchange in a one-pot procedure by Cbz 
to accomplish the oxidative cleavage of the terminal double bond under modified 
Johnson-Lemieux conditions (Scheme 5). The obtained aldehyde 10 was submitted to a 
second aminoallylation reaction with (R)- or (S)-N-tert-butylsulfinamides. Gratifyingly, 
as occurred in the case of the 6-6-5-tetraponerines, the stereocontrol exerted by the 
sulfinyl group overcomes the influences of the chiral aldehyde moiety. Consequently, 
protected diamines 11 and 12 could be obtained in good isolated yields and excellent 
diastereoselectivities after column chromatography (>99:1 dr by HPLC). In this case the 
match-mismatched effect was stronger than with piperidine-derivative substrates, 
achieving a 90% yield of diasteromerically pure 11 after purification (94:6 dr before 
chromatography) and a 69% yield of 12 isolated as a single isomer after purification 
(only 78:22 dr before chromatography). Contrary to what was observed for the 
piperidine aldehyde 2, in this case the matched product was obtained when (S)-N-tert-
butylsulfinamide was used. Importantly, we were able to confirm the absolute 
configuration of diamine derivative 12 by single crystal X-ray analysis27 and it was 
found to be consistent with the stereochemistry predicted by our working model for the 
aminoallylation step.20 Finally, the syntheses of (+)−T1 and (+)−T2 were completed 
after acidic deprotection, catalytic hydrogenation and reaction of both free diamines 
with 4-bromobutanal. The GC-MS data obtained shows essentially one peak with a 
fragmentation pattern that perfectly matched with the one reported for T1 and T2.9 
Moreover, the 1H and 13C-NMR of the obtained T2 also shows a good correlation with 
the data described in the literature.15 However, the NMR spectral data obtained for T1 
shows more signals that the ones described in the literature for this tetraponerine (a very 
minor component in the natural source).28 Contrary to what has been observed for the 
other tetraponerines prepared, this worst NMR correlation could be explained if 
different isomers of T1 with different configurations at C11a are under equilibrium. 
Scheme 5. Synthesis of Tetraponerines (+)−T1 and (+)−T2 
 
Finally, tetraponerines T5 and T6 were prepared by including in the reaction sequence 
the cross-metathesis step of diamine derivatives 11 of 12, respectively, with cis-3-
hexene (Scheme 6). After acidic treatment and catalytic hydrogenation, the obtained 
free diamines were treated, as in other cases, with 4-bromobutanal to obtain the 
corresponding tetraponerines in moderate overall yields. Once again, the GC-MS of 
compounds T5 and T6,9 as well as the NMR data for T6,13b and 29  were in good 
agreement with the literature. However, the NMR data obtained for compound T5 
showed more signals than the previously reported30. Since the same disagreement was 
found for T1 we hypothesized that these 5-6-5 tetraponerines with (S)-configuration at 
C5 are actually a mixture of different aminal isomers in equilibrium with comparable 
energies. However, this hypothesis was not further confirmed. 
Scheme 6. Synthesis of Tetraponerines (+)−T5 and (+)−T6 
 
 
The Bolhmann Bands in IR Spectra of Tetraponerines. 
A brief comment is in order here related to the use of the Bohlmann bands to assign the 
configuration at C5 of tetraponerines.31 The relevant region of the IR spectra obtained 
for the synthesized tetraponerines are shown in Figure 3. The presence of bands for C-H 
stretching at relatively low vibrational frequencies (2780-2810 cm-1) can be observed 
for the IR spectra obtained for the synthesized tetraponerines. The origin of these so 
called Bohlmann bands is not accurately known but has been related to the lengthening 
of C-Haxial bonds due to the hyperconjugation of the adjacent nitrogen lone pair with the 
antiperiplanar antibonding C-H orbitals (n ? σ* C-H).32  
 Figure 3. Bohlmann bands in the IR spectra of tetraponerines. 
As reported,9 the even-numbered tetraponerines (T2, T4, T6 and T8) with (S)-
configuration at C5 show a more severe deviation on this C-H bands which appear at 
lower vibrational frequencies and more intense, compare to the odd-numbered 
tetraponerines (T1, T3, T5 and T7). It is reasonable to consider that the configurational 
analyses performed for T3 and T4 by DFT calculations16 can be extrapolated to T7 and 
T8. Consequently, the even-numbered tetraponerines (T4 and T8) must be mainly 
populated by a ttt-isomer while the ttc is the major isomer for T3 and T7. As depicted in 
Figure 2, ttt-T4 and ttt-T8 exhibit two nitrogen atoms with electron pairs antiperiplanar 
to 5 C-H bonds, whereas ttc-isomers exhibit only one N−lone pair antiperiplanar to 3 
C−H bonds. Consequently, the Bohlmann bands pattern of the 6-6-5-tetraponerines can 
be rationalized in terms of the facility for hyperconjugation of nitrogen lone pairs with 
antiperiplanar C-H bonds. Extrapolation of this explanation to the 5-6-5-tetraponerines 
is not straightforward, especially to the light of our NMR data for T1 and T5. However, 
the same pattern is observed for the Bohlmann bands and their use to predict the 
configuration at C5 of tetraponerines is still valid.  
 
Biological assays 
The biological activities of tetraponerines have been only briefly examined probably 
due to their poor availability either by isolation from their natural source or by chemical 
synthesis. Among the few studies accomplished, an assessment of the anticancer 
activity of some natural tetraponerines and their analogues against HT-29 cell line 
(colorectal carcinoma), showed that the larger hydrocarbonated chain at the C5, the 
lower IC50 values were obtained.6 With this precedents we decided to evaluate the 
cytoxicity of pentyl-side-chain tetraponerines ((+)−T5 to (+)−T8) at 4 different human 
carcinoma cell lines from different origins (A2780 from ovary carcinoma, NCI-H460 
from lung, Caco-2 from colon and MCF-7 from breast). In order to predict the 
therapeutic range, we also screened these compounds over a non-tumoral cell line 
(MRC-5, lung fibroblasts). At a first step, all the compounds were assayed at 100 µM 
and for those compounds showing a decrease in cell viability higher than 50%, a 
concentration-response curve was assayed in order to evaluate their cytotoxic potency 
(IC50). Unfortunately, in most of the cases the cellular growth inhibition was not enough 
to calculate the IC50 value, nevertheless, (+)−T7 showed promising results against 
A2780, MCF-7 (cellular growth inhibition > 50%), being more efficient against MCF-7 
cancer cells. However, (+)−T7 also showed a good percentage of inhibition at MRC-5 
cell lines which could lead to non-specific toxic effects (Table 1). 
Table 1. Cellular Growth Inhibition Percentage of (+)−T5, (+)−T6, (+)−T7 and 
(+)−T8 at 100 µM against Human Cell Linesa 
 Cell line 
Compound NCI-H460b Caco-2c A2780c MCF-7c MRC-5d
CDDP 68 58 96 89 90 
(+)-T5 29 20 40 49 43 
(+)-T6 40 28 30 27 26 
(+)-T7 48 41 62 82 55 
(+)-T8 21 12 49 49 35 
a Cell lines: NCI-H460, lung carcinoma; Caco-2, colon carcinoma; A2780, ovary carcinoma; MCF-7, 
breast carcinoma; MRC-5, human lung fibroblast cells. b48 h cellular growth inhibition (%) as determined 
by MTT. c 96 h cellular growth inhibition (%) as determined by MTT. d 7 d cellular growth inhibition (%) 
as determined by MTT. MTT = (3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide). CDDP 
(cis-diaminedichloroplatinum(II)) was used as control. 
 
The inhibition/concentration curves were obtained for (+)−T7 against the cell lines 
where the cellular growth inhibition was above 50% in order to calculate the IC50 values 
(Table 2). 33 For A2780 and MRC-5 cell lines, the obtained IC50 values were above 100 
µM and solubility problems did not allow achieving the maximum inhibitory 
concentration. However, an acceptable value of IC50 (45 ± 3 µM) was obtained against 
MCF-7 cancer cells.  
 
Table 2. Assessment of Cytotoxicity (IC50, µM) of (+)−T7 against Human Cell 
Linesa 
  Cell line  
Compound A2780b MCF-7b MRC-5c 
CDDP 0.86 ± 0.01 8.18 ± 0.56 5.72 ± 0.14 
(+)-T7 >100 45 ± 3  >100 
a Cell lines: A2780, ovary carcinoma; MCF-7, breast carcinoma; MRC-5, human lung fibroblast cells. b 
Determined after 96 h using the MTT method. c Determided after 7 d using the MTT method. MTT = (3-
[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide). CDDP (cis-diaminedichloroplatinum(II)) 
was used as control. 
 
It is worth mentioning that in previous studies it was concluded that the cytotoxicity of 
tetraponerine analogs against HT29 cancer cells was independent of the configuration at 
C5.6 In this study we have found that the antiproliferative activity of (+)-T7 is 
consistently bigger than that of (+)-T8 against another three different human cell lines.  
 
CONCLUSION 
In summary, the iterative use of stereoselective aminoallylation of aldehydes with chiral 
N-tert-butylsulfinamide and in situ generated allyl indium reagent provides a convenient 
access to all natural tetraponerines from easily available starting materials. The 
formation of the tricyclic aminal scaffold was achieved by reaction of the corresponding 
free enantioenriched diamines with 4-bromobutanal, with concomitant N4 alkylation. 
The configuration at the aminal carbon center was thermodynamically controlled with 
excellent selectivity in the synthesis of any natural tetraponerine, except for (+)−T1 and 
(+)−T5. Interestingly, this methodology allows the access not only to the eight natural 
tetraponerines, but also to their eight enantiomers, by only changing the (R)-tert-
butylsulfinamide for the also commercially available (S)-enantiomer in the first 
aminoallylation step. Importantly, the cross metathesis step could be extended to the use 
of other alkenes, being possible the synthesis of a wide range of tetraponerine analogues 
for their biological evaluation. The antiproliferative activity of (+)−T5 to (+)−T8 
against four different carcinoma cell lines show that the configuration at C5 could be 
important in their potency. Compound (+)−T7 showed a promising cytotoxic profile at 
breast carcinoma cell line MCF-7 when compared with its effect at non-tumoral cell 
lines. With these results we think that further evaluation of tetraponerines (+)−T7 and 
(+)−T8 -or analogues with the same scaffold- against other cancer cell lines is pertinent 
in future works.  
 
EXPERIMENTAL SECTION 
General Remarks. TLC was performed on silica gel 60 F254, using aluminum plates and 
visualized with phosphomolybdic acid (PMA) stain. Flash chromatography was carried out on 
handpacked columns of silica gel 60 (230 − 400 mesh). Melting points are uncorrected. Optical 
rotations were measured using a polarimeter with a thermally jacketted 5 cm cell at 
approximately 20 ºC and concentrations (c) are given in g/100 mL. Infrared analysis was 
performed with a spectrophotometer equipped with an ATR component; wavenumbers are 
given in cm-1. Mass spectra (EI) were obtained at 70 eV; and fragment ions in m/z with relative 
intensities (%) in parentheses. HRMS analyses were carried out using the Electron Impact (EI) 
mode at 70 eV or by Q-TOF using Electro Spray Ionization (ESI) mode. GC analyses were 
obtained with an HP-5 column (30 m × 0.25 mm, ID × 0.25 µm) and an EI (70 EV) detector. 
The temperature program: hold at 60 ºC for 3 min, ramp from 60 ºC to 270 ºC at 15 ºC/min, 
hold at 270 ºC for 10 min. 1H NMR spectra were recorded at 300 or 400 MHz for 1H NMR and 
75 or 100 MHz for 13C NMR, using CDCl3 or C6D6 as the solvent and TMS as an internal 
Standard (0.00 ppm). The data is being reported as (s = singlet, d = doublet, t = triplet, m = 
multiplet or unresolved, br s = broad signal, coupling constant(s) in Hz, integration). 13C NMR 
spectra were recorded with 1H-decoupling at 100 MHz and referenced to CDCl3 at 77.16 ppm 
and to C6D6 at 127.00 ppm. DEPT-135 experiments were performed to assign CH, CH2 and 
CH3. 
Biological procedures:  Procedures used for biological assays are described in the Supporting 
Information. 
Experimental procedures and full characterization data for previously reported 
compounds. Procedure as well as complete characterization data for compounds 1,20a 2, 3, 4, 
T3 and T4 were previously described by our group.16 
(2R,2'R,SS)-(N-Benzyloxycarbonyl)-2-[(2’-tert-butylsulfinamide)-4’-heptenyl]piperidine 
(5). The corresponding homoallylamine 3 (464 mg, 1.16 mmol) was placed in four different dry 
Schlenck tubes under Argon atmosphere (116 mg each).34 In each flask, the homoallylamine 
was disolved in dry CH2Cl2 (5 mL). Then Ti(Oi-Pr)4 (27 µL, 0.09 mmol), cis-3-hexene (143 µL, 
1.16 mmol) and Grubbs-II catalyst (7 mg, 0.009 mmol) were added sequentially. The reaction 
mixtures were heated at 40 ºC for 6 h. After that time, all reactions were collected together and 
the solvent removed under reduced pressure. The residue obtained was purified by column 
chromatography (3:2 hexane/EtOAc). The expected product 5 was obtained as a colorless wax 
(391 mg, 79%). Rotamers are present: [α]20D + 50.5 (c 1.01, CHCl3); Rf 0.21 (1:1 
hexane/EtOAc); IR ν 3242, 2935, 2867, 1677, 1421, 1352, 1260, 1173, 1142, 1064, 730 cm-1; 
1H NMR (300 MHz, CDCl3) δ 7.43 – 7.30 (m, 5H), 5.62 – 5.42 (m, 1H), 5.37 – 5.26 (m, 1H), 
5.14 (t, J = 12.5 Hz, 2H), 4.91 – 4.33 (m, 2H), 4.05 (br d, J = 12.9 Hz, 1H), 2.91 (br s, 1H), 2.77 
(t, J = 12.4 Hz, 1H), 2.39 (br s, 1H), 2.35 – 2.19 (m, 1H), 2.11 – 1.89 (m, 3H), 1.82 – 1.33 (m, 
7H), 1.20 (s, 9H), 1.02 – 0.94 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 155.8 (C), 
136.9 (C), 135.4 (CH), 128.5 (CH), 127.9 (CH), 127.8 (CH), 125.4 (CH), 67.1 (CH2), 55.6 (C), 
53.4 (CH3), 47.6 (CH), 39.3 (CH2), 39.2 (CH2), 36.2 (CH2), 29.3 (CH2), 25.7 (CH2), 25.6 (CH2), 
22.8 (CH), 19.2 (CH2), 13.9 (CH3); GC tR = 20.0 min; LRMS (EI) m/z (%) 378 (M+ - C4H8, 0.1), 
328 (3), 241 (8), 218 (31), 175 (8), 174 (58), 92 (8), 91 (100); HRMS (ESI) calcd for 
C24H39N2O3S (M++1) 435.2681, found 435.2670. 
(2R,2'S,RS)-(N-Benzyloxycarbonyl)-2-[(2’-tert-butylsulfinamide)-4’-heptenyl]piperidine 
(6). The expected product 6 was obtained from 4 (337 mg, 0.83 mmol) as a colorless wax (299 
mg, 83%) following the same procedure described for 5. Rotamers are present: [α]20D – 17.6 (c 
1.05, CHCl3); Rf 0.21 (1:1 hexane/EtOAc); IR ν 3239, 2932, 2867, 1692, 1422, 1259, 1172, 
1065, 1053, 697 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.42 – 7.30 (m, 5H), 5.70 – 5.47 (m, 1H), 
5.41 – 5.24 (m, 1H), 5.20 – 5.03 (m, 2H), 4.48 (s, 1H), 4.06 (d, J = 12.0 Hz, 1H), 3.22 (dd, J = 
12.4, 6.1 Hz, 1H), 2.89 (t, J = 13.1 Hz, 1H), 2.40 (s, 1H), 2.29 (s, 1H), 2.11 – 1.91 (m, 3H), 1.88 
– 1.53 (m, 7H), 1.50 – 1.32 (m, 1H), 1.17 (s, 9H), 0.97 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 155.4 (C), 137.4 (C), 136.9 (CH), 128.6 (CH), 128.6 (CH), 128.0 (CH), 127.9 (CH), 
67.1 (CH2), 55.9 (C), 52.9 (CH), 47.8 (CH), 39.5 (CH2), 39.3 (CH2), 34.5 (CH2), 27.9 (CH2), 
25.8 (CH2), 25.6 (CH2), 22.7 (CH3), 18.9 (CH2), 14.1 (CH3); GC tR = 19.9 min; LRMS (EI) m/z 
(%) 378 (M+ - C4H8, 0.1), 328 (3), 241 (8), 218 (31), 175 (8), 174 (58), 92 (8), 91 (100); HRMS 
(ESI) calcd for C24H39N2O3S (M++1) 435.2681, found 435.2671. 
Tetraponerine T7. To a solution of compound 5 (300 mg, 0.765 mmol) in THF (2 mL) was 
added aqueous 6 M HCl (383 µL, 2.30 mmol) at 0 ºC under Ar. The reaction mixture was 
stirred for 1 h while reaching 23 ºC. Aqueous 2 M NaOH (3 mL) was added to the reaction 
mixture and the free amine was extracted with EtOAc (3 x 10 mL) and washed with brine (1 x 
10 mL). The organics were dried over MgSO4, filtered and concentrated under reduced pressure. 
The residue was then dissolved in dry MeOH (15 mL) and Pd/C 10% (256 mg) was added to the 
mixture. The suspension was shacked under hydrogen atmosphere (4 atm.) for 12 h at 23 ºC, 
filtered through Celite and the obtained solution was concentrated under reduced pressure. The 
residue (free diamine) was then dissolved in dry CH2Cl2 (8 mL) and K2CO3 (317 mg, 2.30 
mmol) was added, followed by 4-bromobutanal35 (207 mg, 1.377 mmol). The reaction mixture 
was stirred at 23 ºC for 4 h, after which time inorganic salts were removed by filtration. The 
filtrate was washed twice with aqueous NaHCO3, followed by brine and then dried over MgSO4. 
The organics were concentrated under reduced pressure and the residue was purified by column 
chromatography (96:4:0.05 CH2Cl2/ MeOH/ 20% NH4OH) to provide the desired product as an 
oil (102 mg, 54%): [α]20D + 30 (c 0.82, CHCl3), [lit.13b [α]20D + 29.5 (c 2.2, CHCl3)]; Rf 0.50 (9:1 
CH2Cl2/MeOH); IR ν 2954, 2926, 2855, 2803, 1455, 1389, 1346, 1156, 1129, 1118 cm-1; 1H 
NMR (300 MHz, C6D6) δ 3.03 (dd, J = 4.4, 2.7 Hz, 1H), 2.90 (dd, J = 14.6, 7.5 Hz, 1H), 2.57 – 
2.46 (m, 3H), 1.83 – 1.73 (m, 1H), 1.68 (dd, J = 12.5, 5.2 Hz, 1H), 1.58 – 1.20 (m, 9H), 1.16 – 
0.90 (m, 10H), 0.87 – 0.81 (m, 1H), 0.64 (t, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
75.5 (CH), 56.7 (CH), 53.3 (CH), 50.9 (CH2), 50.6 (CH2), 34.1 (CH2), 32.5 (CH2), 32.2 (CH2), 
31.0 (CH2), 30.5 (CH2), 27.3 (CH2), 26.4 (CH2), 25.1 (CH2), 23.2 (CH2), 22.2 (CH2), 14.4 
(CH3); GC tR = 13.8 min; LRMS (EI) m/z (%) 251 (M+1, 6), 250 (M+, 44), 249 (82), 207 (19), 
194 (14), 193 (100), 180 (14), 179 (10), 165 (6), 152 (34), 151 (11), 138 (10), 110 (12), 96 (30), 
84 (10), 55 (6); HRMS (ESI) calcd for C16H31N2  (M++1) 251.2487, found 251.2486. 
Tetraponerine T8. Tetraponerine T8 was obtained from 6 (205 mg, 0.49 mmol) as a yellow oil 
(74 mg, 60%) following the same procedure described for T7: [α]20D + 99 (c 0.70, CHCl3), 
[lit.13b [α]20D + 101 (c 2.0, CHCl3)]; Rf 0.40 (9:1 CH2Cl2/MeOH); IR ν 2928, 2857, 2790, 2775, 
1631, 1454, 1377, 1338, 1188, 1156, 1035 cm-1; 1H NMR (300 MHz, C6D6) δ 3.26 (td, J = 8.1, 
2.2 Hz, 1H), 2.98 – 2.91 (m, 1H), 2.42 (t, J = 6.8 Hz, 1H), 2.23 (ddd, J = 11.0, 7.3, 3.7 Hz, 1H), 
2.19 – 2.08 (m, 1H), 1.91 – 1.66 (m, 8H), 1.65 – 1.24 (m, 14H), 1.01 (t, J = 6.9 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 85.6 (CH), 62.7 (CH), 61.4 (CH), 51.5 (CH2), 49.0 (CH2), 38.0 
(CH2), 34.6 (CH2), 32.9 (CH2), 32.8 (CH2), 29.7 (CH2), 26.2 (CH2), 25.2 (CH2), 25.1 (CH2), 
23.1 (CH2), 20.2 (CH2), 14.3 (CH3); GC tR = 14.2 min; LRMS (EI) m/z (%) 251 (M+1, 6), 250 
(M+, 45), 249 (100), 207 (19), 194 (13), 193 (95), 180 (20), 179 (11), 165 (12), 152 (45), 151 
(15), 138 (12), 137 (10), 110 (14), 96 (30), 84 (16), 55 (9); HRMS (ESI) calcd for C16H31N2  
(M++1) 251.2487, found 251.2493. 
(4R,RS)-N-(tert-Butylsulfinyl)-7-bromohept-1-en-4-amine (7). To a dry flask were added 
(RS)-N-tert-butylsulfinamide (829 mg, 6.79 mmol) followed by indium powder (968 g, 8.489 
mmol) under Ar. Then a solution of 4-bromobutyraldehyde (1.121 g, 7.470 mmol) in dry THF 
(15.9 ml) and Ti(OEt)4 (3.1 mL, 13.582 mmol,) were added successively and the reaction 
mixture was stirred under Ar for 1 h at 23 ºC. At this time allyl bromide (897 µL, 10.186 mmol) 
was added to the mixture and the reaction was allowed to reach 60 ºC and stirred at that 
temperature for 5 h. The mixture was allowed to reach room temperature and was carefully 
added over a stirring mixture of 4:1 EtOAc/brine (100 mL). The resulted white suspension was 
filtered through a short pad of Celite, washed with EtOAc and organics were concentrated in 
vacuo. The resulted suspension was diluted in 4:1 EtOAc/hexane (50 mL) and filtered again 
through Celite. Organics were concentrated to afford the expected compound 7 (1.783 g, 89%, 
95:5 dr according to 1H NMR) as a colorless wax, pure enough to be used in the next step. To 
provide the spectroscopy data, a sample of homoallylamine 7 was purified by column 
chromatography: Rf 0.13 (7:3 hexane/EtOAc); 1H NMR (300 MHz, CDCl3) δ 5.79 (ddt, J = 
19.6, 9.4, 7.2 Hz, 1H), 5.20 (d, J = 0.7 Hz, 1H), 5.16 (d, J = 3.6 Hz, 1H), 3.41 (t, J = 6.6 Hz, 
3H), 3.27 (d, J = 6.2 Hz, 1H), 2.55 – 2.25 (m, 2H), 2.03 – 1.82 (m, 2H), 1.82 – 1.56 (m, 2H), 
1.22 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 133.8 (CH), 119.5 (CH2), 56.2 (C), 54.5 (CH), 40.7 
(CH2), 33.7 (CH2), 33.6 (CH2), 29.0 (CH2), 22.8 (CH3); GC tR = 14.1 min; LRMS (EI) m/z (%) 
200 (40), 199 (100), 198 (39), 197 (95), 118 (15), 91 (13), 70 (80), 68 (16), 57 (66). 
(2R,Rs)-2-Allyl-(N-tert-butylsulfinyl)pyrrolidine (8). A titrated solution of KHMDS in THF 
(7.9 mL, 1.03 M, 8.136 mmol) was added via syringe to a cold solution (0 ºC) of crude 7 (1.600 
g, 5.424 mmol) in dry THF (13.8 mL). The reaction mixture was stirred for 1.5 h at 0 ºC under 
Ar, quenched with saturated NH4Cl solution and allowed to reach room temperature. The 
aqueous phase was extracted with EtOAc (3 times) and the combined extracts were washed with 
brine, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by 
column chromatography (80:20 hexane/EtOAc) to provide the product as a colorless oil (1.008 
g, 86%, 97:3 dr according to the 1H-NMR): [α]D20 – 17.1 (c 1.038, CHCl3); Rf 0.30 (7:3 
hexane/EtOAc); IR ν 3076, 2658, 2871, 1639, 1474, 1456, 1361, 1065, 994, 911 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 5.82 – 5.66 (m, 1H), 5.11 – 5.01 (m, 2H), 3.74 (ddd, J = 10.1, 6.6, 3.7 Hz, 
1H), 3.51 – 3.43 (m, 1H), 3.14 (dt, J = 10.7, 7.0 Hz, 1H), 2.52 – 2.43 (m, 1H), 2.17 (ddd, J = 
14.0, 9.4, 8.2 Hz, 1H), 1.87 – 1.73 (m, 3H), 1.71 –1.60 (m, 1H), 1.19 (s, 9H); 13C NMR (101 
MHz, CDCl3) δ 135.3 (CH), 117.3 (CH2), 58.1 (C), 57.5 (CH), 48.6 (CH2), 39.0 (CH2), 30.4 
(CH2), 24.2 (CH2), 23.7 (CH3); GC tR = 11.9 min; LRMS (EI) m/z (%) 215 (M+, 0.1), 159 (16), 
118 (100), 117 (29), 70 (10), 57 (13); HRMS (EI) calcd for C11H21NOS 215.1344, found 
215.1348. 
(R)-2-Allyl-(N-benzyloxycarbonyl)pyrrolidine (9). An aqueous 6 M solution of HCl (2 mL, 
12.00 mmol) was added to a solution of 8 (860 mg, 4.0 mmol) in dry THF (4 mL) at 0 ºC under 
Ar. The solution was allowed to reach 23 ºC and was stirred for 2 h. After cooled again to 0 ºC, 
an aqueous 2 M solution of NaOH (14 mL, 27.00 mmol) was carefully added and the resulting 
mixture was stirred at the same temperature. After 5 min, a solution of benzyloxicarbonyl 
chloride (670 µL, 4.70 mmol) in CH2Cl2 (12 mL) was added to the stirring solution. The 
resulting mixture was then allowed to reach 23 ºC and stirred for 3 h. The reaction mixture was 
extracted with EtOAc (3 times) and the combined organic layers were washed with H2O, dried 
over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by 
column chromatograpy (95:5 hexane/EtOAc) to provide the desired product 9 as a colorless oil 
(831 mg, 85%). Rotamers are present: [α]D20 + 53.1 (c 0.617, CHCl3); Rf 0.60 (7:3 
hexane/EtOAc); IR ν 3035, 2972, 2876, 1696, 1639, 1446, 1407, 1355, 1100 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 7.41 – 7.27 (m, 5H), 5.83 – 5.64 (m, 1H), 5.21 – 4.96 (m, 4H), 3.92 (br s, 
1H), 3.52 – 3.35 (m, 2H), 2.51 (br d, J = 54.4 Hz, 1H), 2.15 (td, J = 14.8, 8.1 Hz, 1H), 1.96 – 
1.70 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 155.1 (C), 154.9 (C), 137.3 (C), 137.1 (C), 135.2 
(CH), 135.0 (CH), 128.6 (CH), 127.9 (CH), 117.4 (CH2), 66.8 (CH2), 66.6 (CH2), 57.4 (CH), 
56.9 (CH), 47.0 (CH2), 46.7 (CH2), 39.1 (CH2), 38.2 (CH2), 30.2 (CH2), 29.3 (CH2), 23.8 (CH2), 
23.0 (CH2); GC tR = 14.6 min; LRMS (EI) m/z (%) 245 (M+, 0.1), 204 (26), 160 (28), 91 (100); 
HRMS (EI) calcd for C15H19NO2 245.1416, found 245.1427. 
(R)-(N-Benzyloxycarbonyl)-2-(2-oxoethyl)pyrrolidine (10). To a solution of 9 (790 mg, 3.224 
mmol) in 1,4-dioxane:H2O (3:1, 30 mL) were successively added 2,6-lutidine (751 µL, 6.45 
mmol), NaIO4 (2.8 g, 12.90 mmol) and a solution of OsO4 in t-BuOH (2.5 % wt in t-BuOH, 317 
µL). The mixture was stirred at 23 ºC for 1.5 h before being quenched with water (20 mL). The 
mixture was extracted with EtOAc (3 x 10 mL) and the collected organic layers were washed 
with H2O, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was 
purified by column chromatograpy (4:1 hexane/EtOAc) to provide the pure product as a 
colorless oil (639 mg, 80%). Rotamers are present: [α]D20 + 40.4 (c 1.44, CHCl3); Rf 0.24 (7:3 
hexane/EtOAc); IR ν 3031, 2956, 2879, 2726, 1718, 1692, 1497, 1448, 1409, 1356, 1100 cm-1; 
1H NMR (300 MHz, CDCl3) δ 9.80 (br s, 0.6H), 9.67 (br s, 0.4H), 7.44 – 7.29 (m, 5H), 5.24 – 
5.01 (m, 2H), 4.32 (dt, J = 12.1, 5.9 Hz, 1H), 3.58 – 3.27 (m, 2H), 2.99 (dd, J = 16.5, 3.1 Hz, 
0.6H), 2.83 (br d, J = 16.8 Hz, 0.4H), 2.53 (d, J = 7.6 Hz, 0.6H), 2.48 (d, J = 7.6 Hz, 0.4H), 2.14 
(dq, J = 12.5, 7.9 Hz, 1H), 1.92 – 1.81 (m, 2H), 1.74 – 1.61 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 200.9 (CH), 200.6 (CH), 155.0 (C), 154.7 (C), 136.9 (C), 136.6 (C), 128.6 (CH), 
128.3 (CH), 128.1 (CH), 128.0 (CH), 67.1 (CH2), 66.9 (CH2), 53.1 (CH), 52.3 (CH), 49.4 (CH2), 
48.7 (CH2), 46.9 (CH2), 46.5 (CH2), 32.1 (CH2), 31.3 (CH2), 23.9 (CH2), 23.1 (CH2); GC tR = 
15.4 min; LRMS (EI) m/z (%) 247 (M+, 0.6), 219 (10), 160 (10), 156 (10), 112 (10), 91 (100), 
65 (10); HRMS (EI) calcd for C14H17NO3 247.1208, found 247.1213. 
(2R,2'R,SS)-(N-Benzyloxycarbonyl)-2-[2’-(tert-butylsulfinamine)-4’-pentenyl]pyrrolidine 
(11). To a dry flask were added (SS)- N-tert-butylsulfinamide (134 mg, 1.107 mmol) and indium 
powder (158 mg, 1.38 mmol) under Ar. Then was added a solution of aldehyde 10 (301 mg, 
1.218 mmol) in dry THF (2.7 ml) followed by Ti(OEt)4 (500 µL, 2.22 mmol) and the reaction 
mixture was stirred under Ar for 1 h at 23 ºC . At this time allyl bromide (143 µL, 1.66 mmol) 
was added to the mixture and it was heated to 60 ºC for 5 h. The mixture was allowed to reach 
23 ºC and was carefully added over a stirring mixture of 4:1 EtOAc/brine (15 mL). The resulted 
white suspension was filtered through a short pad of Celite, washed with EtOAc and the 
organics were concentrated under reduced pressure. According to HPLC analysis (Chiralcel 
AD-H column 25 cm x 0.46 cm, isocratic elution with 95:5 n-hexane/i-PrOH, 1.0 mL/min, UV 
detection at 217 nm), the crude reaction mixture showed a major diastereoisomer at 16.17 min 
(94%) and other diastereoisomers at 20.80 - 23.50 min (6%). After column chromatography (3:2 
hexane/EtOAc), the major isomer was isolated pure (>99:1 dr according to HPLC) as a colorless 
wax product as a unique diastereoisomer after purification by column chromatography (391 mg, 
90%). Rotamers are present: [α]D20 + 83.2 (c 1.220, CHCl3); Rf 0.20 (1:1 hexane/EtOAc); IR ν 
3243, 3065, 2957, 2888, 1685, 1452, 1409, 1360, 1099, 1062 cm-1; 1H NMR (300 MHz, CDCl3) 
δ 7.44 – 7.28 (m, 5H), 5.80 (dq, J = 10.0, 6.9 Hz, 0.8H), 5.62 (dd, J = 15.8, 8.3 Hz, 0.2H), 5.27 
– 5.00 (m, 5H), 4.34 (dd, J = 13.0, 7.6 Hz, 0.8H), 3.99 (br s, 0.2H), 3.42 (dt, J = 11.4, 8.5 Hz, 
2H), 3.20 (qd, J = 10.1, 5.5 Hz, 1H), 2.52 (dt, J = 14.5, 7.4 Hz, 1H), 2.42 – 2.27 (m, 1H), 2.09 – 
1.81 (m, 3H), 1.81 – 1.54 (m, 3H), 1.24 (s, 7H), 1.12 (s, 2H); 13C NMR (101 MHz, CDCl3) δ 
156.3 (C), 137.0 (C), 135.6 (CH), 134.1 (CH), 128.6 (CH), 128.0 (CH), 127.8 (CH), 119.0 
(CH2), 117.5 (CH2), 67.3 (CH2), 66.9 (CH2), 55.6 (C), 54.9 (CH), 53.3 (CH), 46.6 (CH2), 42.4 
(CH2), 41.3 (CH2), 39.8 (CH2), 39.2 (CH2), 31.4 (CH2), 23.8 (CH2), 23.0 (CH3), 22.7 (CH3); GC 
tR = 22.7 min; LRMS (EI) m/z (%) 336 (M+, 0.8), 287 (6), 218 (14), 204 (10), 174 (10), 160 
(20), 114 (6), 91 (100), 70 (23); HRMS (EI) calcd for C21H32N2O3S – C4H8 336.1508, found 
336.1510. 
(2R,2'S,RS)-(N-Benzyloxycarbonyl)-2-[(2’-tert-butylsulfinamine)-4’-pentenyl]pyrrolidine 
(12). Compound 12 was prepared from aldehyde 10 (301 mg, 1.218 mmol) and (RS)-N-tert-
butylsulfinamide (134 mg, 1.107 mmol) following the same procedure described above for 
compound 11. According to HPLC analysis (Chiralcel AD-H column 25 cm x 0.46 cm, isocratic 
elution with 95:5 n-hexane/i-PrOH, 1.0 mL/min, UV detection at 217 nm), the crude reaction 
mixture showed a major diastereoisomer at 21.4 min (78%) and other diastereoisomers at 14.4 - 
17.0 min (22%). After column chromatography (3:2 hexane/EtOAc), the major isomer was 
isolated pure (>99:1 dr according to HPLC) as a colorless wax (301 mg, 69%): mp 76.5 – 77.1 
˚C; [α]D20 - 31.8 (c 0.929, CHCl3); Rf 0.16 (1:1 hexane/EtOAc); IR ν 3203, 3075, 2958, 2883, 
1689, 1471, 1453, 1407, 1096, 1045, 1032 cm-1; Rotamers are present (as shown in the X-ray at 
the Supporting Information) 1H NMR (300 MHz, CDCl3) δ 7.48 – 7.32 (m, 5H), 5.94 – 5.58 (m, 
1H), 5.27 – 4.94 (m, 4H), 4.04 (br d, J = 35.6 Hz, 1H), 3.58 – 3.36 (m, 2.6H), 3.28 (br d, J = 
32.9 Hz, 1H), 3.02 (d, J = 8.4 Hz, 0.4H), 2.58 – 2.31 (m, 2H), 2.09 – 1.80 (m, 4H), 1.68 (br d, J 
= 5.1 Hz, 1H), 1.51 – 1.35 (m, 1H), 1.22 (s, 5H), 1.06 (s, 4H); 13C NMR (101 MHz, CDCl3) δ 
154.9 (C), 137.1 (C), 137.0 (C), 134.0 (CH), 133.3 (CH), 128.7 (CH), 128.6 (CH), 128.4 (CH), 
128.0 (CH), 127.9 (CH), 119.8 (CH2), 119.2 (CH2), 67.2 (CH2), 66.6 (CH2) 56.4 (C), 56.2 (C), 
55.2 (CH), 54.6 (CH), 54.5 (CH), 54.3 (CH), 46.7 (CH2), 46.4 (CH2), 42.2 (CH2), 42.0 (CH2), 
40.3 (CH2), 39.5 (CH2), 30.5 (CH2), 30.1 (CH2), 23.9 (CH2), 23.1 (CH2), 22.9 (CH3), 22.7 
(CH3); GC tR = 22.9 min; LRMS (EI) m/z (%) 336 (M+, 0.8), 287 (6), 218 (14), 204 (10), 174 
(10), 160 (25), 114 (12), 91 (100), 70 (23); HRMS (EI) calcd for C21H32N2O3S – C4H8 336.1508, 
found 336.1509. 
Tetraponerine T1. Tetraponerine T1 was prepared from 11 (300 mg, 0.765 mmol) and 4-
bromobutanal (207 mg, 1.377 mmol) following the same procedure described above for 
compound T7, affording the expected product as an oil (51 mg, 32 % from 11). Configurational 
isomers must be present:36 [α]D20 + 14 (c 0.498, CHCl3) [lit.15 [α]20D + 11 (c 0.14, CHCl3)]; Rf 
0.15 (95:5 CH2Cl2/MeOH); IR ν 2954, 2928, 2871, 2792, 2639, 2585, 1457, 1381, 1349, 1191, 
1167, 1111  cm-1; 1H NMR (300 MHz, CDCl3) δ 3.92 – 3.74 (m, 1H), 3.46 – 3.15 (m, 2H), 3.14 
– 2.88 (m, 2H), 2.77 – 2.36 (m, 1H), 2.31 – 1.78 (m, 8H), 1.79 – 1.16 (m, 7H), 0.92 (t, J = 7.3 
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 77.0 (CH), 58.4 (CH), 53.7 (CH), 50.4 (CH2), 49.8 
(CH2), 33.8 (CH2), 30.8 (CH2), 29.5 (CH2), 29.2 (CH2), 21.3 (CH2), 20.5 (CH2), 20.1 (CH2), 
14.3 (CH3); GC tR = 11.6 min;  LRMS (EI) m/z (%) 208 (M+, 46), 207 (100), 180 (12), 179 (91), 
165 (10), 138 (51), 137 (19), 124 (23), 110 (17), 96 (64), 70 (29); HRMS (EI) calcd for 
C13H24N2 208.1939, found 208.1929. 
Tetraponerine T2. Tetraponerine T2 was prepared from 12 (230 mg, 0.587 mmol), and 4-
bromobutanal (159 mg, 1.057 mmol) following the same procedure described above for 
compound T7, affording the expected product as an oil (42 mg, 35 % from 12); [α]D20 + 47 (c 
0.232, CHCl3), [lit.15 [α]20D + 36 (c 1.79, CHCl3)]; Rf  0.15 (95:5 CH2Cl2/MeOH); IR ν 2955, 
2931, 2871, 2787, 2695, 1457, 1379, 1362, 1190, 1162, 1099  cm-1; 1H NMR (300 MHz, C6D6) 
δ 3.17 – 2.93 (m, 3H), 2.60 – 2.51 (m, 1H), 2.43 (td, J = 8.7, 5.1 Hz, 1H), 2.07 – 1.83 (m, 5H), 
1.83 – 1.60 (m, 4H), 1.60 – 1.25 (m, 7H), 1.01 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, C6D6) δ 
83.0 (CH), 63.8 (CH), 59.1 (CH), 48.6 (CH2), 45.5 (CH2), 36.5 (CH2), 32.7 (CH2), 30.4 (CH2), 
28.9 (CH2), 21.1 (CH2), 20.8 (CH2), 19.3 (CH2), 14.6 (CH3); GC tR = 11.9 min; LRMS (EI) m/z 
(%) 208 (M+, 41), 207 (100), 180 (8), 179 (53), 165 (11), 138 (59), 137 (20), 124 (25), 110 (18), 
96 (47), 70 (37); HRMS (EI) calcd for C13H24N2 208.1939, found 208.1932. 
(2R,2'R,SS)-(N-Benzyloxycarbonyl)-2-[(2’-tert-butylsulfinamine)-4’-heptenyl]pyrrolidine 
(13). Compound 13 was prepared from 11 (513 mg, 1.31 mmol) following the same procedure 
described above for compound 5, affording the corresponding product as a colorless wax (473 
mg, 86%). Rotamers are present: [α]20D + 81.6 (c 1.20, CHCl3); Rf 0.31 (1:1 hexane/EtOAc); IR 
ν 3248, 3031, 2958, 2931, 1685, 1453, 1409, 1359, 1099, 1062, 968, 697 cm-1; 1H NMR (300 
MHz, CDCl3) δ 7.46 – 7.31 (m, 5H), 5.66 – 5.48 (m, 1H), 5.47 – 5.29 (m, 1H), 5.29 – 5.03 (m, 
2H), 4.42 – 3.89 (m, 1H), 3.56 – 3.05 (m, 3H), 2.42 (dt, J = 14.1, 7.1 Hz, 1H), 2.34 – 2.19 (m, 
1H), 1.23 (s, 7H), 1.12 (s, 2H), 1.18 (d, J = 34.3 Hz, 9H), 0.96 (t, J = 7.4 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ 156.1 (C), 137.0 (C), 135.4 (CH), 128.6 (CH), 128.0 (CH), 127.8 (CH), 
125.6 (CH), 66.9 (CH2), 55.7 (C), 55.0 (CH), 53.5 (CH), 46.5 (CH2), 42.2 (CH2), 38.0 (CH2), 
31.3 (CH2), 25.8 (CH2), 23.8 (CH2), 22.9 (CH3), 22.7 (CH3), 14.3 (CH3), 13.9 (CH3); GC tR = 
19.4 min; LRMS (EI) m/z (%) 314 (3), 227 (3), 204 (12), 173 (4), 161 (3), 160 (23), 145 (24), 
92 (8), 91 (100), 70 (6), 69 (3), 65 (5); HRMS (ESI) calcd for C23H37N2O3S (M++1) 421.2525, 
found 421.2521. 
(2R,2'S,RS)-(N-Benzyloxycarbonyl)-2-[(2’-tert-butylsulfinamine)-4’-heptenyl]pyrrolidine 
(14). Compound 14 was prepared from 12 (358 mg, 0.90 mmol) following the same procedure 
described above for compound 5, affording the corresponding product as a colorless wax (295 
mg, 78%). Rotamers are present: [α]20D − 20.5 (c 0.99, CHCl3); Rf 0.30 (1:1 hexane/EtOAc); IR 
ν 3232, 3030, 2959, 2873, 1691, 1454, 1412, 1359, 1102, 1057, 970, 750 cm-1; 1H NMR (300 
MHz, CDCl3) δ 7.41 – 7.30 (m, 5H), 5.59 (dt, J = 15.2, 6.4 Hz, 1H), 5.47 – 5.22 (m, 1H), 5.22 – 
4.97 (m, 2H), 4.18 – 3.87 (m, 1H), 3.59 – 3.00 (m, 4H), 2.34 (br d, J = 21.0 Hz, 2H), 2.11 – 1.92 
(m, 4H), 1.92 – 1.59 (m, 3H), 1.37 (dd, J = 24.1, 12.3 Hz, 1H), 1.23 (s, 5H), 1.05 (s, 4H), 0.97 
(t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 154.7 (C), 137.7 (CH), 137.2 (CH), 136.9 
(C), 136.8 (C), 128.4 (CH), 128.2 (CH), 127.9 (CH), 127.7 (CH), 123.8 (CH), 123.1 (CH), 67.0 
(CH2), 66.5 (CH2), 56.1 (C), 55.9 (C), 55.1 (CH), 54.6 (CH), 54.4 (CH), 46.6 (CH2), 46.2 (CH2), 
40.6 (CH2), 40.5 (CH2), 40.2 (CH2), 39.3 (CH2), 30.4 (CH2), 29.9 (CH2), 25.7 (CH2), 23.7 
(CH2), 22.8 (CH3), 22.5 (CH3), 20.7 (CH2), 14.2 (CH3), 13.9 (CH3); GC tR = 19.4 min; LRMS 
(EI) m/z (%) 314 (3), 227 (3), 207 (3), 204 (11), 179 (3), 174 (4), 173 (4), 161 (3), 160 (23), 145 
(9), 92 (8), 91 (100), 70 (6), 65 (4); HRMS (ESI) calcd for C23H37N2O3S (M++1) 421.2525, 
found 421.2519. 
Tetraponerine T5. Tetraponerine T5 was prepared from 13 (460 mg, 1.10 mmol), and 4-
bromobutanal following the same procedure described above for compound T7, affording the 
expected product as a yellow oil (90 mg, 35%). Configurational isomers must be present:36 
[α]20D + 14 (c 1.60, CHCl3), [lit.15 [α]20D + 10 (c 0.24, CHCl3)]; Rf 0.35 (9:1 CH2Cl2/MeOH); IR 
ν 3414, 2953, 2927, 2857, 2793, 1457, 1384, 1348, 1233, 1162, 1114, 1064 cm-1; 1H NMR (300 
MHz, CDCl3) δ 3.75 – 3.45 (m, 1H), 3.40 – 2.64 (m, 4H), 2.62 – 2.15 (m, 1H), 2.16 – 1.43 (m, 
12H), 1.40 – 0.98 (m, 7H), 0.89 (dd, J = 9.0, 4.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 59.9 
(CH), 58.3 (CH), 53.9 (CH), 50.3 (CH2), 49.5 (CH2), 31.9 (CH2), 31.3 (CH2), 30.6 (CH2), 29.3 
(CH2), 29.0 (CH2), 26.9 (CH2), 22.6 (CH2), 21.1 (CH2), 20.0 (CH2), 14.1 (CH3); GC tR = 13.0 
min; LRMS (EI) m/z (%) 237 (5), 236 (M+, 42), 235 (100), 193 (13), 180 (12), 179 (81), 166 
(15), 165 (6), 152 (11), 138 (27), 137 (12), 124 (10), 110 (21), 96 (43), 70 (18), 55 (7); HRMS 
(ESI) calcd for C15H29N2 (M++1) 237.2331, found 237.2324. 
Tetraponerine T6. Tetraponerine T6 was prepared from 14 (255 mg, 0.61 mmol), and 4-
bromobutanal following the same procedure described above for compound T7, affording the 
expected product as a yellow oil (52 g, 36%); [α]20D + 40 (c 0.75, CHCl3), [lit.15 [α]20D + 35 (c 
0.31, CHCl3)]; Rf 0.50 (9:1 CH2Cl2/MeOH); IR ν 3395, 2954, 2928, 2858, 2784, 1458, 1378, 
1204, 1188, 1161, 1064 cm-1; 1H NMR (300 MHz, C6D6) δ 3.11 – 3.01 (m, 1H), 2.94 (td, J = 
8.4, 2.5 Hz, 1H), 2.85 (t, J = 5.3 Hz, 1H), 2.48 – 2.36 (m, 1H), 2.32 (dd, J = 8.4, 5.3 Hz, 1H), 
2.00 – 1.84 (m, 2H), 1.83 – 1.52 (m, 7H), 1.50 – 1.19 (m, 11H), 0.91 (t, J = 6.9 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 83.4 (CH), 64.2 (CH), 59.7 (CH), 49.1 (CH2), 45.9 (CH2), 34.7 
(CH2), 33.5 (CH2), 32.6 (CH2), 30.6 (CH2), 29.2 (CH2), 25.9 (CH2), 23.1 (CH2), 21.3 (CH2), 
20.9 (CH2), 14.4 (CH3); GC tR = 13.3 min; LRMS (EI) m/z (%) 237 (M+1, 5), 236 (M+, 40), 235 
(100), 207 (5), 193 (15), 180 (8), 179 (54), 166 (17), 165 (10), 152 (13), 151 (10), 138 (38), 137 
(14), 124 (12), 123 (5), 110 (14), 97 (7), 96 (35), 70 (24), 68 (7), 55 (6); HRMS (ESI) calcd for 
C15H29N2 (M++1) 237.2331, found 237.2333. 
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